The Late Breaking Session presented data on new insights into FA disease mechanisms and positive results in an FA omaveloxolone clinical trial, a novel SCA5 screening platform to identify new drug targets & the discovery of a novel gene causing SCA50.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Report of euro-ATAXIA research conference (3 November 2012) | 5 | 1662 | December 23, 2012 | |
| Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Friedreich’s Ataxia | 0 | 1704 | June 23, 2017 | |
| FDA Awards Philadelphia Researcher $2 Million to Study Natural History of Friedreich’s Ataxia | 2 | 1536 | October 20, 2017 | |
| Current research news | 6 | 1916 | September 28, 2015 | |
| Friedreich’s Ataxia Research Collaboration Announced | 0 | 1840 | July 31, 2015 |